Application of stc2 gene as a molecular marker for colorectal cancer liver metastasis

Abstract

The invention discloses application of an STC2 gene as a colorectal cancer liver metastasis molecular marker. The invention provides a kit for identifying or assisting in identifying whether a to-be-detected colorectal cancer patient has liver metastasis or not. The kit comprises a reagent for detecting expression quantity of the STC2 gene and a carrier for recording the following judgment standards: if the expression quantity of the STC2 gene in a cancer tissue of the to-be-detected colorectal cancer patient is higher than that of the STC2 gene in the cancer tissue of the diagnosed non-liver metastasis colorectal cancer liver patient, and the two have remarkable difference, the to-be-detected colorectal cancer patient has or is candidate to have liver metastasis. Experiments in the invention prove that expression of the STC2 in primary lesion of patients in the colorectal cancer liver metastasis group is remarkably higher than that in a non-liver metastasis group, and in-vitro functional experiment result at a later period indicates that STC2 possibly promotes tumor metastasis invasion ability to participate in a colorectal cancer liver metastasis process, so that clue is provided for further finding the colorectal cancer liver metastasis molecular marker.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an application of STC2 gene as a molecular marker of colorectal cancer liver metastasis. Background technique [0002] Colorectal cancer is a common malignant tumor of the digestive tract, and its incidence is second only to gastric cancer and esophageal cancer. The most important factor affecting the prognosis of patients with colorectal cancer is cancer metastasis, among which liver metastasis is the most common. According to statistics, 20%-40% of patients with colorectal cancer have developed liver metastases when they are diagnosed, and the incidence of metachronous liver metastases is as high as 50%. The average survival period of patients with liver metastases without treatment is 16-18 months, while the survival period of patients with extensive metastasis is only 3-5 months. The vast majority of patients with liver metastases cannot be radically resected due to factors suc...

AI Technical Summary

Problems solved by technology

In the study of markers related to tumor metastasis of colorectal cancer, although a lot of research has been done, a marker with high enough sensitivity and specificity that is suitable for early diagnosis has not yet been found.

Images